Abstract
Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have